Trials / Completed
CompletedNCT02808494
Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers
Prospective Collection of Whole Blood Specimens of Subjects Diagnosed With Preeclampsia With Severe Features and/or Fetal Growth Restriction in Support of a Molecular Assay Development
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 242 (actual)
- Sponsor
- Illumina, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Sample Collection Study
Detailed description
This is a limited prospective collection of whole blood samples from pregnant women with a diagnosis of preeclampsia with severe features and/or fetal growth restriction in addition to samples from a control group to aid in the development of a Next Generation Sequencing (NGS)-based assay to detect molecular markers associated with preterm preeclampsia.
Conditions
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2017-11-20
- Completion
- 2017-11-20
- First posted
- 2016-06-21
- Last updated
- 2022-04-29
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02808494. Inclusion in this directory is not an endorsement.